Newsletter

Pol. Merkur. Lek (Pol. Med. J.), 2012, XXXII/190: 217-220 Maximize

Pol. Merkur. Lek (Pol. Med. J.), 2012, XXXII/190: 217-220

Title: Immunomodulatory drugs in the treatment of primary systemic light chain amyloidosis

Authors: Charliński G., Wiater E., Jędrzejczak W.W.

More details

01/190

40,00 zł

SUMMARY IN POLISH & ENGLISH. FULL ARTICLE ONLY IN POLISH.

Immunomodulatory drugs in the treatment of primary systemic light chain amyloidosis


Charliński G., Wiater E., Jędrzejczak W.W.

Medical University of Warsaw, Poland, Department of Hematology, Oncology and Internal Diseases

Primary systemic immunoglobulin light chain amyloidosis (AL.) is an incurable clonal plasma cell disorder in which fragments of Ig light chain are deposited in tissues. High dose melphalan and hematopoietic cell transplantation (SCT) is a preferred technique, but only 20% of patients are eligible. Nontransplant candidates can be offered MelDex (melphalan-dexamethasone). Demonstrate comparable efficacy of treatment protocols including immunomodulatory drugs such as TCD (thalidomide, cyclophosphamide, dexamethasone), LMP (lenalidomide, melphalan, prednisone), or bortezomib in combination with dexamethasone. Results of treatment of patients with AL. based on immunomodulatory drugs are promising but require further multicenter clinical trial comparing the MelDex. The main obstacle to effective treatment of AL. still remains a late diagnosis of the disease.

Key words: primary systemic light amyloidosis, immunomodulatory drugs, proteasome inhibitors, treatment

Pol. Merk. Lek., 2012, XXXII, 190, 217